ZHONGSHENGYAOYE(SZ:002317) Xinda Securities·2026-01-19 10:35Investment Rating - The report assigns a "Buy" rating for the stock of Zhongsheng Pharmaceutical (002317) based on its potential for strong performance relative to the benchmark index [11]. Core Insights - The successful licensing agreement for RAY1225 injection with Qilu Pharmaceutical is expected to enhance domestic commercialization prospects [1][3]. - RAY1225 is a GLP-1/GIP dual-target peptide drug with promising pharmacokinetic properties, allowing for bi-weekly administration, and has completed participant enrollment in three Phase III clinical trials [2]. - The partnership with Qilu Pharmaceutical, a major player in the Chinese pharmaceutical market, is anticipated to maximize future commercialization benefits for Zhongsheng [3]. Financial Projections - Revenue forecasts for Zhongsheng Pharmaceutical are projected at RMB 2.601 billion, RMB 2.978 billion, and RMB 3.449 billion for the years 2025, 2026, and 2027 respectively, with corresponding net profits of RMB 301 million, RMB 395 million, and RMB 508 million [4]. - The expected EPS (diluted) for the same years is projected to be RMB 0.35, RMB 0.47, and RMB 0.60, with P/E ratios of 61.17, 46.58, and 36.29 respectively [4].